Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Scinai Immunotherapeutics Reports Promising Results in Psoriatic Skin Model
Details : Scinai's anti IL-17A/F VHH antibody fragment is a local, first of its kind, intralesional treatment for the large and underserved population of patients with mild to moderate plaque psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 15, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Scinai Announces Promising Results in a Psoriatic Human Skin Model
Details : Scinai Immunotherapeutics is developing a IL-17A Inhibitor antibody drug candidate, which is currently being evaluated for the treatment of patients with mild to moderate plaque psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NanoAbs (alpaca-derived nanosized antibody) also known as VHH-antibodies, exhibit potential as biobetter therapies for a wide range of diseases. Scinai is developing NanoAbs addressing diseases with large unmet medical needs and attractive commercial opp...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : GIBF2
Deal Size : $8.0 million
Deal Type : Financing
Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
Details : The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : GIBF2
Deal Size : $8.0 million
Deal Type : Financing
Lead Product(s) : BX005
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Maruho
Deal Size : Undisclosed
Deal Type : Agreement
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
Details : Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study of atopic dermatitis product candidate, BX005, in Japan.
Product Name : BX005
Product Type : Microorganism
Upfront Cash : Undisclosed
October 13, 2021
Lead Product(s) : BX005
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Maruho
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : BX005
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vitro results with BX005 demonstrated a broad host range and efficient eradication of Staphylococcus aureus strains with no mutants arising after 24 hours, versus untreated strains showing normal growth.
Product Name : BX005
Product Type : Microorganism
Upfront Cash : Inapplicable
June 14, 2021
Lead Product(s) : BX005
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable